Evidence summary

Obstruction of either the central airways or superior vena cava is a complication of cancer which can cause severe breathlessness.

Although high level evidence to support these treatments is lacking, treatment guidelines recommend that for central airway obstruction causing dyspnoea, either endobronchial treatments (laser, brachytherapy, electrocautery, cryosurgery, stenting) or external beam radiotherapy may provide effective palliation. [1,2] A systematic review comparing external beam radiotherapy plus brachytherapy for obstruction with external beam radiotherapy alone showed no strong evidence to support adding brachytherapy to external beam radiotherapy. External beam radiotherapy alone seemed to be more effective than brachytherapy. [3]

Chemotherapy should be considered, where clinically appropriate, as the first line treatment for chemosensitive tumours causing obstruction. [4] There is evidence that both endovascular stenting and radiotherapy are effective in malignant superior vena cava obstruction. [1-2]

Steroids are frequently recommended for palliation in superior vena cava obstruction, but this practice has not been studied.
Dyspnoea associated with obstruction can be severe and distressing. If active interventions are either inappropriate or impossible, palliation should focus on pharmacologically minimising distress for the patient (and for their family and caregivers) by promptly treating with opioids, and / or anxiolytics and sedatives. [5-6]


Practical implications

  • Chemotherapy should be considered, where clinically appropriate, as the first line treatment for chemosensitive tumours causing obstruction. [4]
  • Based on a recent systematic review, patients with non-small cell lung cancer who have recurrent obstruction after being treated with external beam radiotherapy, could be considered for treatment with brachytherapy. [3]
  • Referral for stenting or radiotherapy for superior vena cava obstruction, or radiotherapy, stenting or endobronchial treatment for central airway obstruction should be offered if clinically appropriate.
  • Dyspnoea associated with obstruction can be severe and distressing and a focus on pharmacologically minimising distress for the patient (and for their family and caregivers) may be appropriate. Consider treating with opioids, anxiolytics or other sedatives. [5-6]


  1. Kvale PA, Simoff M, Prakash UB; American College of Chest Physicians. Lung cancer. Palliative care. Chest. 2003 Jan;123(1 suppl):284S-311S.
  2. Scottish Intercollegiate Guidelines Network (SIGN). Management of lung cancer. A national clinical guideline. 2014 Feb;SIGN publication no. 137.
  3. Reveiz L, Rueda JR, Cardona AF. Palliative endobronchial brachytherapy for non-small cell lung cancer. Cochrane Database Syst Rev. 2012 Dec 12;12:CD004284.
  4. Ripamonti C. Management of dyspnea in advanced cancer patients. Support Care Cancer. 1999 Jul;7(4):233-43.
  5. Salacz ME, Weissman DE. Controlled sedation for refractory suffering: part 1. J Palliat Med. 2005 Feb;8(1):136-7.
  6. Cherny N, Radbruch L. European Association for Palliative Care (EAPC) recommended framework for the use of sedation in palliative care. Palliat Med. 2009 Oct;23(7):581-93.

Last updated 27 August 2021